Petrochemicals in the first quarter: Bazan's dividend arrived, but most value still runs through debt

The first quarter did not change the story around Petrochemicals, but it did close one important checkpoint: the dividend from Bazan was received after the balance-sheet date and was used for an early redemption of Series I debt. That is positive, because the cash moved from an approved dividend into actual debt reduction. The same movement also sharpens the main constraint: value at the holding company still first passes through the creditor layer before it can become accessible value for ordinary shareholders. The company reported a NIS 55.1 million loss, mainly because of finance expenses and remeasurement effects, while operating cash flow was negative NIS 0.9 million and cash at quarter-end was only NIS 5.5 million. The operating asset had a stronger quarter, with a sharp increase in reported and adjusted EBITDA, but at the holding-company level that has not yet turned into meaningful free cash. A post-quarter event reinforces the point: the company expects the roughly 8% decline in the dollar-shekel exchange rate after March 31 to reduce equity by about NIS 61 million on a net basis. This was a quarter that proved the mechanism, not one that solved the structure: a dividend arrived, debt went down, but the next proof points remain additional dividends, reduction or refinancing of Series J, and evidence that more of the value can move beyond creditors.

The Bazan stake still drives the whole story

Petrochemicals is almost a pure holding company. Through its PCH subsidiary, it holds 769.7 million shares of Bazan, equal to about 24.7% of issued share capital and about 24.2% on a fully diluted basis. That means almost every number in the report should be read through three layers: the value of the stake, the debt secured against much of that value, and the cash that is actually available at the holding company.

The previous annual analysis argued that the company entered 2026 with more time and less immediate pressure, but not with a new independent repayment source. A follow-up analysis of repayment sources emphasized that dividends and repurchases of old debt series are the key questions on the road to 2027. The first quarter confirms that direction. It does not show a new business, a new customer, or a separate operating cash engine. It shows movement within the same structure: one central asset, meaningful debt, and a dividend that comes from the asset and is mostly directed to creditors.

The balance sheet shows the gap. The central investment is carried at NIS 1.35 billion. Against it stand liabilities to holders and financial creditors of NIS 574.1 million gross and NIS 526.5 million at amortized cost. Current assets total NIS 72.3 million, but that is not the same as a free cash pile: NIS 39.3 million is restricted cash, mostly the deposit with the Series K trustee, and NIS 27.3 million is a receivable dividend that was approved in late March and paid only after quarter-end.

The dividend closed one checkpoint, not the 2027 problem

The most important event in the quarter is not in the profit line. On March 25, 2026, Bazan's board approved a $35 million dividend for 2025 results. Petrochemicals's share was $8.66 million, about NIS 27.3 million, and the amount was paid on April 26, 2026. On May 7, 2026, the company made a partial early redemption of Series I debt totaling NIS 23.8 million, including principal, interest and linkage.

This matters because it turns an approved dividend into cash received and debt repaid. But it also shows where the money goes. The dividend did not materially expand ordinary shareholder flexibility. It moved almost immediately into debt reduction. That is not negative in itself, because lowering debt is a prerequisite for releasing value later. Still, it prevents investors from reading the dividend as an economic distribution to common shareholders.

The all-in cash picture for the quarter remained narrow. Operating cash flow was negative NIS 0.9 million, withdrawal from restricted deposits contributed NIS 0.4 million, and financing cash flow was negative NIS 0.2 million, mainly due to a bond repurchase partly offset by option exercises. Cash ended March at NIS 5.5 million. The company also says it has no external financing sources available for repayment of its liabilities and is not rated. The real issue is therefore not whether one dividend arrived, but how many additional dividends arrive before the next debt dates and what happens to Series J.

Bazan improved operationally, Petrochemicals lost on accounting mechanics

The gap between Bazan's report and Petrochemicals's report is where a first read can go wrong. At the Bazan level, the quarter improved year over year: revenue rose to $1.94 billion from $1.56 billion, reported EBITDA increased to $89 million from $27 million, and adjusted EBITDA as presented by Bazan rose to $154 million from $40 million. Bazan's reported net loss narrowed to $8 million from $31 million.

At the Petrochemicals level, the picture was different. The company's share in an associate's results, net, was a NIS 6.2 million loss, an improvement from a NIS 27.7 million loss in the prior-year quarter. But net finance expenses jumped to about NIS 47.9 million, compared with about NIS 1.4 million if finance income is netted against finance expense in the prior-year quarter. The result was a NIS 55.1 million net loss, compared with NIS 31.2 million in the first quarter of 2025.

The reason is not ordinary operations. A large part of the expense relates to remeasurements and debt instruments: fair-value changes in the deferred benefit to holders and financial liabilities, remeasurement of Series J, and dollar-rate effects on net shekel liabilities. These are not current-quarter operating cash outflows, but they are not meaningless noise. They affect accounting equity, the relationship between the stake value and debt, and how much of Bazan's future value remains after the creditor layer.

The dollar and debt dates decide the next quarters

Petrochemicals's equity declined to NIS 823.3 million at the end of March, from NIS 870.9 million at the end of 2025. After the report date, the company gave a sharper illustration: the dollar fell from NIS 3.165 to about NIS 2.908 near publication, a decline of about 8%. The company estimates that this move will reduce the translated value of the Bazan investment by about NIS 110 million, partly offset by a NIS 49 million decrease in financial liabilities, for a net equity reduction of about NIS 61 million.

This is not a cash movement, but it shows why high accounting equity is not the same as accessible cash. Holding-company value depends on the central asset's share price, the exchange rate, the fair value of debt mechanisms, and the pace at which dividends become debt reduction. At the same time, the central asset still has financing access: the filings mention an ilA+ rating affirmation with a negative outlook, three long-term bank loans of $40 million, $40 million and $50 million, and expanded short-term credit facilities to $280 million until the end of September 2026.

The test for the next two to four quarters is clear: additional distributions from Bazan, reduction or refinancing of Series J on terms that do not erode shareholders, and a stake value that does not decline faster than debt. If those three items move together, this quarter will look like the start of an orderly debt-reduction process. If not, the March dividend will remain a one-off event that lowered short-term pressure but did not change the company's dependence on one asset and on creditors that stand ahead of shareholders.